News BerGenBio ASA

Equities

BGBIO

NO0010650013

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-10 am EDT			5-day change	1st Jan Change
0.1388 ^NOK	+1.31%		-2.53%	-50.07%

Mar. 20	Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	CI
Feb. 14	BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BerGenBio ASA: Notice of Annual General Meeting	Apr. 30	AQ
BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2023	Apr. 30	AQ
BerGenBio ASA: New share capital registered	Apr. 25	AQ
BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission	Apr. 17	AQ
BerGenBio - Disclosure of shareholding	Apr. 17	AQ
BerGenBio - Disclosure of large shareholding	Apr. 17	AQ
BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue	Apr. 16	AQ
BerGenBio ASA, Mandatory notification of trade by primary insiders and close associates	Apr. 16	AQ
BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates	Apr. 15	AQ
BerGenBio ASA: Last day of the last exercise period for warrants issued in connection with rights issue	Apr. 15	AQ
BerGenBio ASA: Last day of trading in warrants	Apr. 08	AQ
Mandatory notification of trade by related party to Primary Insiders	Apr. 08	AQ
BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue	Apr. 03	AQ
BerGenBio ASA: Commencement of the last exercise period for warrants issued in connection with rights issue	Apr. 02	AQ
BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025	Apr. 02	AQ
BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025	Apr. 02	AQ
BerGenBio ASA, Exercise price in the last exercise period for warrants issued in connection with rights issue	Mar. 28	AQ
BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue	Mar. 27	AQ
Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	Mar. 20	CI
BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation	Mar. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BerGenBio ASA

Equities

BGBIO

NO0010650013

Summary

Filters